Research & Development
Prostate Cancer: Page 2
Avenda Health gets FDA 510(k) clearance for iQuest prostate cancer platform
The iQuest platform provides physicians with a 3D visualization, enabling treatment decisions that consider the extent of the cancer rather than treating the whole organ.
December 8, 2022
MDxHealth sees Medicare delay for prostate cancer risk test, reduces 2022 revenue guide
To obtain Medicare payments for the test, the firm had to submit a Technical Assessment for review and consideration under a Local Coverage Decision (LCD) process recently implemented by the Molecular Diagnostics Services (MolDX) Program.
November 30, 2022
Low-value prostate cancer screening has Medicare spending ramifications, study finds
The consequences of low-value PSA cancer screening could amount to more than $275 million in spending for Medicare, according to the authors' estimates.
November 22, 2022
Higher PSA screening rates associated with less metastatic prostate cancer
Investigators undertook a retrospective cohort study of patients to determine whether facility-level variations in PSA screening rates could be associated with subsequent facility-level metastatic prostate cancer incidence.
October 25, 2022
Veracyte announces data for prostate genomic classifier
September 21, 2022
Veracyte announces data at ESMO 2022 for prostate genomic classifier
The data from a study presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris came from a Phase 3 trial of the multicenter, multinational, randomized STAMPEDE platform protocol. The protocol involves more than 10,000 men to date with high-risk, nonmetastatic or metastatic prostate cancer who are starting long-term androgen-deprivation therapy for the first time and are randomized to new treatments in seven Phase 3 trials.
September 11, 2022
Veracyte to present abstracts at ESMO Congress 2022
The following abstracts will be shared at the event in Paris on September 11:
August 30, 2022
Nanostics secures CE Mark for ClarityDx Prostate
ClarityDx Prostate, which detects and measures extracellular vesicles, is based on a machine-learning algorithm that combines data from biological and clinical biomarkers to generate a risk score for prostate cancer that has a Gleason grade group 2 or higher on prostate biopsy.
August 22, 2022
Genetic risk score may reduce invasive prostate biopsies
In research published Thursday in the British Journal of Cancer, the U.K.-based researchers calculated genetic risk for prostate cancer by leveraging more than 250 known genetic variants that are commonly linked to the disease. These genetic variants were all combined to form a single genetic risk score that could then be used to assess an individual's genetic risk of developing prostate cancer.
August 18, 2022
Deep Bio integrates DeepDx AI algorithm into Halo AP platform
DeepDx Prostate detects prostate cancer in core needle biopsies and grades their severity based on the Gleason scoring system, according to the vendor.
August 9, 2022
MDxHealth buys Exact Sciences’ prostate cancer business
Under the terms of an asset purchase agreement, MDxHealth paid $25 million in cash; $5 million will be settled through the delivery of 691,171 American depositary shares.
August 2, 2022
miR Scientific develops molecular prostate cancer test
miR Sentinel is a molecular test that analyzes small noncoding RNA using a biostatistical algorithm. It assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men under the age of 45 who are at risk for prostate cancer.
July 13, 2022
Page 2 of 7